Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers

Immunological Reviews

Volumn 257, Issue 1, 2014, Pages 226-236

  Ghosh, Arnab ^a,b   Holland, Amanda M ^c   Van den Brink, Marcel R M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Allo HSCT; GVHD; GVT; PLZF; Precursor T cells; TRAIL

Indexed keywords

CYTOTOXIC AGENT; DEATH RECEPTOR; FETAL ANTIGEN; GRANZYME; GRANZYME B; INTERLEUKIN 4; PERFORIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR PLZF; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; GENETIC ENGINEERING; GENETIC ENHANCEMENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INTERNALIZATION; LEUKEMIA RELAPSE; NATURAL KILLER T CELL; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PRE T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT CANCER; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL;

ALLO-HSCT; GVHD; GVT; PLZF; PRECURSOR T CELLS; TRAIL;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; CYTOTOXICITY, IMMUNOLOGIC; GENETIC ENGINEERING; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; PRECURSOR CELLS, T-LYMPHOID; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84890236232     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12142     Document Type: Article

References (99)

1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
2. Schafer A, Friedmann W, Mielke M, Schwartlander B, Koch MA. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 1991;164:593-599.
3. Caussy D, et al. Interaction of human immunodeficiency and papilloma viruses: association with anal epithelial abnormality in homosexual men. Int J Cancer 1990;46:214-219.
4. Cesarman E. Pathology of lymphoma in HIV. Curr Opin Oncol 2013;25:487-494.
5. Chang Y, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-1869.
6. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-727.
7. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-839.
8. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005;437:141-146.
9. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-1570.
10. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-1321.
11. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. PNAS 2004;101:14639-14645.
12. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103:767-776.
13. Kolb HJ, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.
14. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007;25:139-170.
15. Gooley TA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363:2091-2101.
16. Porter DL, Antin JH. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 1999;50:369-386.
17. Odom LF, et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man? Lancet 1978;2:537-540.
18. Sykes M, Chester CH, Sundt TM, Romick ML, Hoyles KA, Sachs DH. Effects of T cell depletion in radiation bone marrow chimeras. III. Characterization of allogeneic bone marrow cell populations that increase allogeneic chimerism independently of graft-vs-host disease in mixed marrow recipients. J Immunol 1989;143:3503-3511.
19. Slavin S, Morecki S, Weiss L, Or R. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res 2002;11:265-276.
20. Falkenburg JH, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999;94:1201-1208.
21. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008;41:483-493.
22. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 2005;11:1244-1249.
23. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 2002;100:1903-1909.
24. Johnson B, Truitt R. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995;85:3302-3312.
25. Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003;111:659-669.
26. Chakraverty R, et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 2006;203:2021-2031.
27. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006;24:419-466.
28. Felix NJ, et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 2007;8:388-397.
29. Oosten LEM, Blokland E, Kester MGD, Falkenburg JHF, van Halteren AGS, Goulmy E. Promiscuity of the AlloHLA-A2 restricted T cell repertoire hampers the generation of minor histocompatibility antigen-specific cytotoxic T cells across HLA barriers. Biol Blood Marrow Transplant 2007;13:151-163.
30. Carnevale-Schianca F, et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood 2006;107:3795-3803.
31. Stelljes M, et al. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8 + T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets. Blood 2004;104:1210-1216.
32. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001;411:385-389.
33. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999;93:2336-2341.
34. de Witte MA, Toebes M, Song JY, Wolkers MC, Schumacher TN. Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease. Blood 2007;109:3830-3838.
35. Kuhns MS, Davis MM, Garcia KC. Deconstructing the form and function of the TCR/CD3 complex. Immunity 2006;24:133-139.
36. Hambach L, et al. Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia 2006;20:371-374.
37. Oosten LE, et al. Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes. Blood 2004;104:224-226.
38. Di Terlizzi S, et al. Therapeutic and diagnostic applications of minor histocompatibility antigen HA-1 and HA-2 disparities in allogeneic hematopoietic stem cell transplantation: a survey of different populations. Biol Blood Marrow Transplant 2006;12:95-101.
39. Leen AM, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12:1160-1166.
40. Gao L, Yang TH, Tourdot S, Sadovnikova E, Hasserjian R, Stauss HJ. Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease. Blood 1999;94:2999-3006.
41. Ghosh A, et al. Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras. Blood 2009;113:4440-4448.
42. de Witte MA, et al. Targeting self-antigens through allogeneic TCR gene transfer. Blood 2006;108:870-877.
43. Bendle GM, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 2010;16:565-570, 561p following 570.
44. Porter D, Levine J. Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion. Semin Hematol 2006;43:53-61.
45. Jiang Z, Podack E, Levy RB. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis. Blood 2001;98:390-397.
46. Chavez-Galan L, Arenas-Del Angel MC, Zenteno E, Chavez R, Lascurain R. Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 2009;6:15-25.
47. Mateo V, et al. Perforin-dependent apoptosis functionally compensates Fas deficiency in activation-induced cell death of human T lymphocytes. Blood 2007;110:4285-4292.
48. Law RH, et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature 2010;468:447-451.
49. Lopez JA, Brennan AJ, Whisstock JC, Voskoboinik I, Trapani JA. Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends Immunol 2012;33:406-412.
50. Ewen CL, Kane KP, Bleackley RC. A quarter century of granzymes. Cell Death Differ 2012;19:28-35.
51. Hartmann N, et al. Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions. Blood 2013;121:556-565.
52. Schmaltz C, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 2001;97:2886-2895.
53. Hsieh MH, Korngold R. Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses. Blood 2000;96:1047-1055.
54. Bian G, et al. Granzyme B-mediated damage of CD8 + T cells impairs graft-versus-tumor effect. J Immunol 2013;190:1341-1350.
55. Graubert TA, Russell JH, Ley TJ. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood 1996;87:1232-1237.
56. Blazar BR, Taylor PA, Vallera DA. CD4 + and CD8 + T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation 1997;64:571-576.
57. Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997;100:904-911.
58. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996;183:2645-2656.
59. Lavrik I, Golks A, Krammer PH. Death receptor signaling. J Cell Sci 2005;118:265-267.
60. Schleich K, Krammer PH, Lavrik IN. The chains of death: a new view on caspase-8 activation at the DISC. Cell Cycle 2013;12:193-194.
61. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene 2007;26:3745-3757.
62. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 2003;18:1-6.
63. Hallett WH, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 2008;180:163-170.
64. Sayers TJ, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003;102:303-310.
65. Schmaltz C, et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 2002;8:1433-1437.
66. Kelley SK, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001;299:31-38.
67. Carlo-Stella C, et al. Antitumor activity of human CD34 + cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther 2006;17:1225-1240.
68. Walczak H, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163.
69. Ghosh A, et al. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. J Clin Invest 2013;123:2654-2662.
70. Serody JS, Hill GR. The IL-17 differentiation pathway and its role in transplant outcome. Biol Blood Marrow Transplant 2012;18:S56-S61.
71. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000;100:655-669.
72. Das J, Chen CH, Yang L, Cohn L, Ray P, Ray A. A critical role for NF-kappa B in GATA3 expression and Th2 differentiation in allergic airway inflammation. Nat Immunol 2001;2:45-50.
73. Ivanov II, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 + T helper cells. Cell 2006;126:1121-1133.
74. Murphy WJ, et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 1998;102:1742-1748.
75. Yang YG, Dey BR, Sergio JJ, Pearson DA, Sykes M. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest 1998;102:2126-2135.
76. Ushiyama C, Hirano T, Miyajima H, Okumura K, Ovary Z, Hashimoto H. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease. J Immunol 1995;154:2687-2696.
77. Kappel LW, et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009;113:945-952.
78. Yi T, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009;114:3101-3112.
79. Kelly KF, Daniel JM. POZ for effect-POZ-ZF transcription factors in cancer and development. Trends Cell Biol 2006;16:578-587.
80. Kovalovsky D, et al. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol 2008;9:1055-1064.
81. Savage AK, et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 2008;29:391-403.
82. Xu D, et al. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity 2009;30:802-816.
83. Raberger J, et al. The transcriptional regulator PLZF induces the development of CD44 high memory phenotype T cells. Proc Natl Acad Sci USA 2008;105:17919-17924.
84. Kovalovsky D, Alonzo ES, Uche OU, Eidson M, Nichols KE, Sant'Angelo DB. PLZF induces the spontaneous acquisition of memory/effector functions in T cells independently of NKT cell-related signals. J Immunol 2010;184:6746-6755.
85. Ghosh A, et al. PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD. Cancer Res 2013;73:4687-4696.
86. Vacchelli E, et al. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013;2:e24238.
87. Stauss HJ, Morris EC. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther 2013;20:1029-1032.
88. Radtke F, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999;10:547-558.
89. Wilson A, MacDonald HR, Radtke F. Notch 1-deficient common lymphoid precursors adopt a B cell fate in the thymus. J Exp Med 2001;194:1003-1012.
90. Schmitt TM, Zuniga-Pflucker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 2002;17:749-756.
91. Schmitt TM, de Pooter RF, Gronski MA, Cho SK, Ohashi PS, Zuniga-Pflucker JC. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol 2004;5:410-417.
92. Ohishi K, Varnum-Finney B, Bernstein ID. Delta-1 enhances marrow and thymus repopulating ability of human CD34(+)CD38(-) cord blood cells. J Clin Invest 2002;110:1165-1174.
93. Mohtashami M, Shah DK, Nakase H, Kianizad K, Petrie HT, Zuniga-Pflucker JC. Direct comparison of Dll1- and Dll4-mediated Notch activation levels shows differential lymphomyeloid lineage commitment outcomes. J Immunol 2010;185:867-876.
94. Dervovic DD, Ciofani M, Kianizad K, Zuniga-Pflucker JC. Comparative and functional evaluation of in vitro generated to ex vivo CD8 T cells. J Immunol 2012;189:3411-3420.
95. Awong G, Herer E, La Motte-Mohs RN, Zuniga-Pflucker JC. Human CD8 T cells generated in vitro from hematopoietic stem cells are functionally mature. BMC Immunol 2011;12:22.
96. Quezada SA, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637-650.
97. Zakrzewski JL, et al. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med 2006;12:1039-1047.
98. Zakrzewski JL, et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol 2008;26:453-461.
99. Holland AM, et al. Extrathymic development of murine T cells after bone marrow transplantation. J Clin Invest 2012;122:4716-4726.